News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent …
Shares of Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) initially surged 3.6% in premarket trading before moderating to a 1% gain after the French pharmaceutical giant agreed [https://seekingalpha.com/pr/20670494-regeneron-and-sanofi-expand-global-alliance-with-multiple-next-generation-long-acting]to a deal worth up to $8B, including $1B upfront with Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) to jointly develop four long-acting immunology therapies. …
Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent …
Sanofi's SNY most important medicine remains its immunology drug, Dupixent, which continues to be the company's primary growth engine. Dupixent sales represented roughly 42% of Sanofi's first-half 2026 revenues. Sanofimarkets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records …
Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio …
Sanofi and Cheplapharm are entering a new strategic partnership where Cheplapharm will acquire 20 mature medicines and three manufacturing sites from Sanofi. In return, Sanofi will gain a 26.4% equity stake in Cheplapharm, building on a collaboration initiated in 2014. This deal allows Sanofi …
Sanofi has set an ambitious €25 billion sales target for Dupixent by 2030, driven by growth in existing markets, pediatric expansion, and geographic reach, particularly in conditions with low biologic penetration like COPD and atopic dermatitis. Ahead of Dupixent's patent expiration in the early …
Bavarian Nordic has appointed Tarja Stenvall, a veteran with leadership experience from Sanofi, AstraZeneca, and Pfizer, as its new CEO, effective October 15. Stenvall replaces Paul Chaplin, who announced his departure earlier this year after 12 years at the helm. She will focus on …
Sanofi has inaugurated a new flu vaccine manufacturing facility, the Charles Best Building, in Toronto. This expansion marks a significant development for Sanofi's vaccine production capabilities. The news was published on September 16, 2026.
The $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soil Built in partnership with the Government of Canada, the Province of Ontario, and the City of Toronto to bolster the country's vaccine biomanufacturing capabilities and support Canada's national response to …
Sanofi is divesting 20 mature medicines and three manufacturing sites to its long-term partner Cheplapharm, a move aimed at allowing Sanofi to focus on innovation. This collaboration, which expands on a decade-long partnership, will see Sanofi receive a 26.4 percent equity stake in Cheplapharm. …
Cheplapharm has announced a strategic partnership with Sanofi to acquire a portfolio of 20 mature medicines and three manufacturing facilities located in Hungary, Singapore, and France. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, expanding on their decade-long working relationship. This …
This article summarizes top news in the pharmaceutical industry, highlighting Sanofi's expanded partnership with Cheplapharm, which involves transferring 20 mature medicines and three manufacturing sites in exchange for a 26.4% equity stake. It also covers GSK's acquisition of a trispecific T-cell engager from Chimagen …
Sanofi has delivered mixed returns over recent years, and with the share price around €75.43, the real issue for you is whether that level is justified by the earnings power the group is producing today. Over the past 3 years, the stock has declined …
Sanofi is divesting 20 older medicines and three manufacturing sites to Cheplapharm in exchange for a 26.4% equity stake in the German drugmaker. This move is part of Sanofi CEO Belén Garijo's strategy to prioritize innovation and free up resources for R&D, especially in …
Sanofi Winthrop Industrie Sanofi and Cheplapharmto create new strategic partnership in mature medicines Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a …
INmune Bio, Inc. Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today …
Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the …
Sanofi has launched a new educational campaign called "Serve Up Protection" in partnership with USA Pickleball to promote its Nuvaxovid COVID-19 vaccine to older adults. The campaign aims to distribute information about the vaccine to a key demographic of pickleball players, leveraging the sport …
Sanofi's drug lunsekimig has successfully met its Phase IIb goals for treating moderate to severe asthma, paving the way for Phase III trials. The trial included 685 adult patients and builds on previous positive data from earlier this year. This development marks a significant …
Despite their risk of serious illness from COVID-19, nearly 70% of adults 65 and older remain unvaccinated, in part due to concerns about potential side effects The campaign serves up COVID-19 prevention education, including details about NUVAXOVID™ and its established tolerability MORRISTOWN, N.J. and …
Sanofi has partnered with USA Pickleball to launch the "Serve Up Protection" campaign, aimed at educating older adults about its COVID-19 vaccine, Nuvaxovid. This initiative targets the demographic that is highly engaged in pickleball but has low COVID-19 vaccination rates, addressing concerns about side …
The European Commission has approved a €400 million German state grant to Sanofi to ensure its insulin production remains in Frankfurt. This subsidy aims to secure Europe's insulin supply and prevent Sanofi from closing its German site, which would increase reliance on imports. In …
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States